Market watch : Pharma industry strategic performance: 2007-2012E.
Goodman
Michael
M
D020533:Angiogenesis Inhibitors / Q000191:economics; D000893:Anti-Inflammatory Agents / Q000191:economics; D000911:Antibodies, Monoclonal / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D014150:Antipsychotic Agents / Q000191:economics; D000068180:Aripiprazole; D000068258:Bevacizumab; D003365:Costs and Cost Analysis; D004345:Drug Industry / Q000191:economics / Q000592:standards / Q000639:trends*; D004358:Drug Therapy / Q000191:economics*; D004335:Drug and Narcotic Control / Q000639:trends; D006801:Humans; D000069285:Infliximab; D008389:Marketing of Health Services / Q000191:economics; D010879:Piperazines / Q000191:economics; D015363:Quinolones / Q000191:economics; D012201:Reward; D014481:United States
D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068258:Bevacizumab; D000068180:Aripiprazole; D000069285:Infliximab